Coexpression of SFRP1 and WIF1 as a Prognostic Predictor of Favorable Outcomes in Patients with Colorectal Carcinoma

Table 4

Correlations between WIF1/SFRP1 protein expression and clinical characteristics of CRC patients.

Characteristics	Cases; (𝑁=127)	Immunoreactive positive (%)
		WIF1	𝑃 value	SFRP1	𝑃 value
Age (year)			0.652		0.704
≤65	66	49 (74.2)		28 (42.4)
>65	79	56 (70.9)		36 (45.6)
Gender			0.273		0.115
Male	80	55 (68.8)		40 (50.0)
Female	65	50 (76.9)		24 (36.9)
Lesion sites			0.704		0.000
Right	87	62 (71.3)		49 (56.3)
Left	58	43 (74.1)		15 (25.9)
Architectural features			0.488		0.835
Mucus	15	12 (80.0)		7 (46.7)
Nonmucinous	130	93 (71.5)		57 (43.8)
Tumor diameter			0.005		0.250
≤4.5 cm	67	41 (61.2)		33 (49.3)
>4.5 cm	78	64 (82.1)		31 (39.7)
Invasion			0.001		0.025
T1	6	2 (33.3)		5 (83.3)
T2	19	15 (78.9)		9 (47.4)
T3	41	22 (53.7)		23 (56.1)
T4	79	66 (83.5)		27 (34.2)
Lymph metastasis			0.096		0.132
N0	84	61 (72.6)		43 (51.2)
N1	24	21 (87.5)		8 (33.3)
N2	37	23 (62.2)		13 (35.1)
Liver metastasis			0.703		0.109
Negative	132	95 (72.0)		61 (46.2)
Positive	13	10 (76.9)		3 (23.1)
TNM stage^a			0.878		0.042
I	29	21 (72.4)		16 (55.2)
II	52	39 (75.0)		27 (51.9)
III	47	34 (72.3)		18 (38.3)
IV	17	11 (64.7)		3 (17.6)

aAccording to the 2002 version of the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC).